Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth B Gordon

Showing results (91-100 of 136) with videos related to

Pageof 14
Sort By:
The British Journal of Dermatology|November 11, 2023
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.
JAMA Dermatology|May 11, 2022
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical TrialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.
American Journal of Clinical Dermatology|August 31, 2025
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb StudiesJoseph F Merola, Richard B Warren, Diamant Thaçi, et al.
Dermatology and Therapy|April 4, 2025
Correction: Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological ConditionsKenneth B Gordon, Yayoi Tada, Milan J Anadkat, et al.
Dermatology and Therapy|February 10, 2025
Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological ConditionsKenneth B Gordon, Yayoi Tada, Milan J Anadkat, et al.
JAMA Dermatology|October 14, 2020
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical TrialsMatthias Augustin, Jo Lambert, Carla Zema, et al.
Dermatology and Therapy|August 17, 2024
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical TrialsKenneth B Gordon, Andrew Blauvelt, Hervé Bachelez, et al.
Journal of the American Academy of Dermatology|October 3, 2006
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyKenneth B Gordon, Richard G Langley, Craig Leonardi, et al.
Journal of the American Academy of Dermatology|October 8, 2011
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trialsKenneth B Gordon, Kim A Papp, Richard G Langley, et al.
Dermatology and Therapy|July 30, 2024
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Pageof 14

Showing results (91-100 of 136) with videos related to

Sort By:
Pageof 14
The British Journal of Dermatology|November 11, 2023
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.
JAMA Dermatology|May 11, 2022
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical TrialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.
American Journal of Clinical Dermatology|August 31, 2025
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb StudiesJoseph F Merola, Richard B Warren, Diamant Thaçi, et al.
Dermatology and Therapy|April 4, 2025
Correction: Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological ConditionsKenneth B Gordon, Yayoi Tada, Milan J Anadkat, et al.
Dermatology and Therapy|February 10, 2025
Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological ConditionsKenneth B Gordon, Yayoi Tada, Milan J Anadkat, et al.
JAMA Dermatology|October 14, 2020
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical TrialsMatthias Augustin, Jo Lambert, Carla Zema, et al.
Dermatology and Therapy|August 17, 2024
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical TrialsKenneth B Gordon, Andrew Blauvelt, Hervé Bachelez, et al.
Journal of the American Academy of Dermatology|October 3, 2006
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyKenneth B Gordon, Richard G Langley, Craig Leonardi, et al.
Journal of the American Academy of Dermatology|October 8, 2011
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trialsKenneth B Gordon, Kim A Papp, Richard G Langley, et al.
Dermatology and Therapy|July 30, 2024
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Pageof 14